A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

Exclusion Criteria

• •1. Presence of other causes of CNV other than wet AMD in the study eye.
• •2. Presence of active diabetic retinopathy in the study eye.
• •3. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥30mmHg despite the standardized treatment).
• •4. Prior retinal detachment in the study eye.
• •5. Prior any treatment of following in the study eye:
• •1. Anti-VEGF therapy within 6 months prior to screening;
• •2. Anti-complement therapy;
• •3. Laser photocoagulation;
• •4. Photodynamic therapy;
• •5. Transpupillary thermotherapy
• •6. Intraocular surgery;
• •7. Intraocular or periocular glucocorticoid injection therapy within 6 months prior to enrollment;
• •6. Presence of any non-AMD disease that may affect visual acuity in the study eye
• •7. Prior anti-VEGF therapy within 1 month before study drug administration or plan of above anti-VEGF therapy in the non-study eye during the whole study.
• •8. Oral steroid drugs within 1 month before study drug administration.
• •9. Presence of active intraocular or periocular inflammation or infection.
• •10. Diabetic patients have any of the following conditions:
• •1. Microvascular and macrovascular complications;
• •2. HbA1c\>7.5% when screening;
• •3. Receiving more than two oral hypoglycemic agents;
• •4. Receiving insulin or GLP-1 receptor agonist;
• •11. Hypertension (defined as systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg despite standard treatment);
• •12. Presence of any following laboratory abnormality:
• •1. PLT\<100×109/L, INR≥1.5ULN, APTT≥ 10 seconds more than ULN;
• •2. ALT or AST \>2ULN;
• •3. Cr or Ur\>1.5ULN;
• •13. Large or medium surgery, or unhealed surgical incisions, ulcers or fractures within 1 month before study drug administration.